Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.

IF 3.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Research in Cardiology Pub Date : 2025-09-08 DOI:10.1007/s00392-025-02739-9

Knut Kröger, Karsten Wiemes, Frans Santosa, Hinrich Böhner, Hildegard Lax, Susanne Stolpe, Bernd Kowall, Andreas Stang

{"title":"Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.","authors":"Knut Kröger, Karsten Wiemes, Frans Santosa, Hinrich Böhner, Hildegard Lax, Susanne Stolpe, Bernd Kowall, Andreas Stang","doi":"10.1007/s00392-025-02739-9","DOIUrl":null,"url":null,"abstract":"Objectives: We investigated changes in lipid-lowering drug prescriptions in Germany as a whole and in the 16 federal states over the last 13 years and their association with hospitalization rates for acute myocardial infarction.Design: Ecological study.Setting: Nationwide German hospitalization, Diagnosis-Related Groups Statistic.Patients/participants: German population in the years 2010 through 2022.Intervention: All prescriptions of lipid-lowering drugs in the years 2010 to 2022 by federal state in Germany.Main outcome measures: Hospitalization rates for the treatment of transmural infarction per calendar year and federal state (STEMI = ST-elevation myocardial infarction).Results: The age-standardized prescription rates of lipid-lowering drugs per 1000 person-years increased from 77.4 in 2010 to 145.2 in 2022 (reference population: Germany 2011). Within the same period, the STEMI hospitalization rate per 100,000 person-years decreased from 143.7 to 100.1. Based on the prescription and hospitalization rates of the 16 federal states, it is shown that the STEMI hospitalization rate decreased the more the prescription rate of lipid-lowering drugs in a federal state increased over time (beta = 0.38, 95% confidence interval - 0.64; - 0.12; adjusted explained variance 0.362).Conclusion: Increasing prescription rates of lipid-lowering drugs have correlated with decreasing rates of hospitalized cases for STEMI in Germany in the last decade.","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-025-02739-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We investigated changes in lipid-lowering drug prescriptions in Germany as a whole and in the 16 federal states over the last 13 years and their association with hospitalization rates for acute myocardial infarction.

Design: Ecological study.

Setting: Nationwide German hospitalization, Diagnosis-Related Groups Statistic.

Patients/participants: German population in the years 2010 through 2022.

Intervention: All prescriptions of lipid-lowering drugs in the years 2010 to 2022 by federal state in Germany.

Main outcome measures: Hospitalization rates for the treatment of transmural infarction per calendar year and federal state (STEMI = ST-elevation myocardial infarction).

Results: The age-standardized prescription rates of lipid-lowering drugs per 1000 person-years increased from 77.4 in 2010 to 145.2 in 2022 (reference population: Germany 2011). Within the same period, the STEMI hospitalization rate per 100,000 person-years decreased from 143.7 to 100.1. Based on the prescription and hospitalization rates of the 16 federal states, it is shown that the STEMI hospitalization rate decreased the more the prescription rate of lipid-lowering drugs in a federal state increased over time (beta = 0.38, 95% confidence interval - 0.64; - 0.12; adjusted explained variance 0.362).

Conclusion: Increasing prescription rates of lipid-lowering drugs have correlated with decreasing rates of hospitalized cases for STEMI in Germany in the last decade.

查看原文本刊更多论文

2010-2022年德国降脂药物处方及其与st段抬高型心肌梗死（STEMI）住院的关系

目的：我们调查了过去13年来德国整体和16个联邦州降脂药物处方的变化及其与急性心肌梗死住院率的关系。设计：生态研究。设置：德国全国住院，诊断相关组统计。患者/参与者：2010年至2022年的德国人口。干预：2010 - 2022年德国联邦各州所有降脂药处方。主要结局指标：每年和联邦州治疗跨壁梗死的住院率（STEMI = st段抬高型心肌梗死）。结果：降脂药的年龄标准化处方率从2010年的77.4 / 1000人年增加到2022年的145.2 / 1000人年（参考人群：德国2011）。在同一时期，STEMI的住院率从每10万人年143.7降至100.1。基于16个联邦州的处方率和住院率，结果表明，随着时间的推移，联邦州的降脂药物处方率越高，STEMI住院率越低（beta = 0.38, 95%置信区间- 0.64;- 0.12；调整后解释方差0.362）。结论：在过去的十年中，德国降脂药物处方率的增加与STEMI住院病例率的下降有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Research in Cardiology 医学-心血管系统

CiteScore

11.40

自引率

4.00%

发文量

140

审稿时长

4-8 weeks

期刊介绍： Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.